
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics Inc. is advancing its flagship program, FHD-909, which shows promising potential in treating serious diseases through innovative mechanisms targeting the chromatin regulatory system. The financial outlook appears favorable, with projections indicating a potential stock increase of 40-50% in the base case scenario and up to 60-90% in the bull case, depending on objective response rates (ORR) and duration of response (DoR). Additionally, FHD-909's demonstrated synergy with chemotherapy and checkpoint inhibitors suggests a robust efficacy, further enhancing the company’s growth prospects as it prepares for upcoming clinical expansions.
Bears say
Foghorn Therapeutics Inc. is facing significant challenges, as its internal clinical data failed to demonstrate a sufficient threshold of clinical benefit, potentially due to limitations related to its lead molecule, prompting a strategic pivot amid balance sheet constraints. Preclinical assessments have indicated that the efficacy of key compounds may be hindered by factors such as slow degradation kinetics and a notable hook effect, resulting in a limited response and durability of effect in clinical settings. Furthermore, the risk-adjusted valuation does not align favorably with market performance expectations, suggesting a potential decline of 30-40% based on current analyst projections.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares